The aim of the project is to study neuromodulation treatment in patients with idiopathic overactive bladder syndrome (OAB) in real clinical practice.
Subjects (male and female) aged 18 years and over
Subjects diagnosed with OAB or mixed urinary incontinence with a predominant urge component who were indicated for treatment with peroneal eTNM
Subjects who consent to the processing of anonymized demographic data and anonymized treatment data with peroneal eTNM
Subjects with contraindications to treatment with peroneal eTNM
Subjects who express their disagreement with the processing of anonymised demographic data and anonymised treatment data with peroneal eTNM
Patients with OAB.
Case-only
Prospective
Peroneal eTNM
Procedure/SurgeryPeroneal electrical transcutaneous neuromodulation (peroneal eTNM) is used to stimulate the peroneal nerve to positively influence the symptoms of OAB.
Patient improvement measured using PGI-I tool
Patient improvement will be measured using validated PGI-I tool. PGI-I is a psychometric rating tool used to measure patient treatment satisfaction on a ranked scale.
Overall treatment effect (OAB-V8)
The overall treatment effect will be measured using the OAB-V8 tool. It is an 8-question medical screening tool used to identify symptoms severity of an overactive bladder (OAB) and measure how much those symptoms bother a patient.
Overall treatment safety
Overall treatment safety will be measured by the number and severity of adverse events.
Predictive factors for clinical treatment success (PGI-I)
Multivariate analysis of predictive factors for clinical treatment success (sex, age, comorbidities, concomitant medication, stimulation parameters).
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
